Novo Nordisk A/S (NONOF)
127.05
-4.15
(-3.16%)
USD |
OTCM |
Jul 26, 16:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 565.76B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 65.67% |
Valuation | |
PE Ratio | 43.86 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 16.03 |
Price to Book Value | 39.54 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | 0.9320 |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.2722 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 24.80% |
Profile
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders. |
URL | https://www.novonordisk.com |
Investor Relations URL | https://www.novonordisk.com/investors.html |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | Large Cap/Growth |
Next Earnings Release | Aug. 07, 2024 |
Last Earnings Release | May. 02, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Mar. 22, 2024 |
Ratings
Profile
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders. |
URL | https://www.novonordisk.com |
Investor Relations URL | https://www.novonordisk.com/investors.html |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | Large Cap/Growth |
Next Earnings Release | Aug. 07, 2024 |
Last Earnings Release | May. 02, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Mar. 22, 2024 |